Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index; 1 of the 56 sources its claims cite were checked for support.

A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)

Open access
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., on behalf of the UK Prospective Diabetes Study (UKPDS) Group · 2004 · Diabetologia

Abstract

AIMS/HYPOTHESIS: The aim of this study was to develop a simulation model for type 2 diabetes that can be used to estimate the likely occurrence of major diabetes-related complications over a lifetime, in order to calculate health economic outcomes such as quality-adjusted life expectancy. METHODS: Equations for forecasting the occurrence of seven diabetes-related complications and death were estimated using data on 3642 patients from the United Kingdom Prospective Diabetes Study (UKPDS). After examining the internal validity, the UKPDS Outcomes Model was used to simulate the mean difference in expected quality-adjusted life years between the UKPDS regimens of intensive and conventional blood glucose control. RESULTS: The model's forecasts fell within the 95% confidence interval for the occurrence of observed events during the UKPDS follow-up period. When the model was used to simulate event history over patients' lifetimes, those treated with a regimen of conventional glucose control could expect 16.35 undiscounted quality-adjusted life years, and those receiving treatment with intensive glucose control could expect 16.62 quality-adjusted life years, a difference of 0.27 (95% CI: -0.48 to 1.03). CONCLUSIONS/INTERPRETATIONS: The UKPDS Outcomes Model is able to simulate event histories that closely match observed outcomes in the UKPDS and that can be extrapolated over patients' lifetimes. Its validity in estimating outcomes in other groups of patients, however, remains to be evaluated. The model allows simulation of a range of long-term outcomes, which should assist in informing future economic evaluations of interventions in type 2 diabetes.

Overview

CoChat Summary

## TL;DR

The paper develops the UKPDS Outcomes Model, a simulation model for Type 2 diabetes that estimates lifetime risk of seven complications and death from data on 3,642 UKPDS patients. It fits the observed UKPDS outcomes closely and estimates that intensive glucose control yields 0.27 more undiscounted QALYs over a lifetime than conventional control, though external validity remains untested.

## Key findings

  • The model was fit using data from 3,642 UKPDS patients, with 39,460 person-years of follow-up and a median follow-up of 10.3 years.
  • Internal validation showed the model’s forecasts fell within the 95% confidence interval for observed events during follow-up, and the simulated cumulative incidence for the seven diabetes-related complications and all-cause mortality was within the observed 95% CIs up to 12 years from diagnosis.
  • For UKPDS patients treated under the trial protocol, the model estimated 16.35 undiscounted QALYs for conventional glucose control and 16.62 for intensive control, a difference of 0.27 QALYs (95% CI: -0.48 to 1.03).
  • Example life expectancy estimates for patients diagnosed at 45–49 years were 25.54 years for men and 26.80 years for women; corresponding quality-adjusted life expectancy was 18.82 and 20.06 QALYs, respectively.

## Methods

  • The paper developed a probabilistic discrete-time illness-death simulation model with annual cycles to estimate first occurrence of seven diabetes-related complications (MI, other IHD, stroke, heart failure, amputation, renal failure, and blindness in one eye) plus death.
  • Event equations were estimated from 3,642 UKPDS patients using Weibull proportional hazards regression for complications, logistic regression for fatality after first events, Gompertz regression for diabetes-related and other mortality, and random-effects panel data regression for progression of HbA1c, systolic BP, total cholesterol:HDL, and smoking status.
  • The model was internally validated by comparing simulated cumulative incidence with non-parametric life-table estimates, and uncertainty was handled with bootstrap plus multiple imputation methods.

## Limitations

  • The paper states the model only predicts the first event in any single category of diabetes-related complications and does not directly model sequences such as sequential amputations.
  • The paper states it does not explicitly incorporate some diabetes-related morbidities, notably peripheral neuropathy and ulceration, and also excludes hypoglycaemia and hyperglycaemia as modeled outcomes.
  • The paper states that external validity remains to be evaluated; this is reinforced by the text’s caution that the model should be used carefully in other populations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00125-004-1527-z

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

1 Valid · 2 Not valid · 40 Not checked · 70 Own results and interpretations

53 more claims

Create a free account to see all 113 claims and to verify the 55 references still open.

See all claims — free account
  • Probably not a substantial claim. 45
  • It may state two separate claims as one. 19
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Cited by

See all 663

Metadata

Authors
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group
Affiliations
  • University of Oxford (GB)
  • University of Nottingham (GB)
  • Churchill Hospital (GB)
Corresponding author
Clarke, P. M.
Venue
Diabetologia
Published
2004-10
Volume
47
Issue
10
Pages
1747-1759
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2126252058
Cited by
615
References
42
Citations by year
2026: 15 · 2025: 21 · 2024: 24 · 2023: 23 · 2022: 40 · 2021: 31 · 2020: 56 · 2019: 24 · 2018: 31 · 2017: 30 · 2016: 41 · 2015: 40 · 2014: 40 · 2013: 35 · 2012: 37
FWCI
27.64
Type
journal article
Language
en
Open access
Licence
  • public-domain
  • www.springer.com/tdm (tdm)
Locations
  • Diabetologia (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, computer simulation, quality-adjusted life years, diabetes complications, tight glycemic control, health economic evaluation, UKPDS
MeSH terms
Amputation, Surgical, Blood Glucose, Cardiovascular Diseases, Computer Simulation, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Retinopathy, Female, United Kingdom, Health Status, Humans, Life Expectancy, Male, Middle Aged, Models, Biological, Quality of Life, Risk Factors, Reproducibility of Results, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). https://app.cochat.ai/papers/10.1007/s00125-004-1527-z
The paper
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group. (2004). A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. https://doi.org/10.1007/s00125-004-1527-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.